Show simple item record

Atomoxetine increases fronto-parietal functional MRI activation in attention-deficit/hyperactivity disorder: a pilot study

dc.contributor.authorBush, George
dc.contributor.authorHolmes, Jennifer
dc.contributor.authorShin, Lisa M.
dc.contributor.authorSurman, Craig
dc.contributor.authorMakris, Nikos
dc.contributor.authorMick, Eric
dc.contributor.authorSeidman, Larry J.
dc.contributor.authorBiederman, Joseph
dc.date2022-08-11T08:10:34.000
dc.date.accessioned2022-08-23T17:13:05Z
dc.date.available2022-08-23T17:13:05Z
dc.date.issued2012-11-10
dc.date.submitted2013-04-10
dc.identifier.citationEpub 2012 Nov 10. <a href="http://dx.doi.org/10.1016/j.pscychresns.2012.09.004">Link to article on publisher's site</a>
dc.identifier.issn0165-1781 (Linking)
dc.identifier.doi10.1016/j.pscychresns.2012.09.004
dc.identifier.pmid23146254
dc.identifier.urihttp://hdl.handle.net/20.500.14038/46645
dc.description.abstractWe hypothesized that atomoxetine (ATMX) would produce similar brain effects in attention-deficit/hyperactivity disorder (ADHD) as those of methylphenidate (MPH). Eleven ADHD adults performed the Multi-Source Interference Task (MSIT) during functional magnetic resonance imaging (fMRI) at baseline and after 6 weeks of ATMX treatment. ATMX was associated with increased fMRI activation of dorsolateral prefrontal cortex, parietal cortex and cerebellum but not dorsal anterior midcingulate cortex (daMCC). These results suggest that ATMX and MPH have similar but not identical brain effects.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=23146254&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1016/j.pscychresns.2012.09.004
dc.subjectBehavioral Disciplines and Activities
dc.subjectBioimaging and Biomedical Optics
dc.subjectPharmacy and Pharmaceutical Sciences
dc.subjectPsychiatry and Psychology
dc.subjectTherapeutics
dc.titleAtomoxetine increases fronto-parietal functional MRI activation in attention-deficit/hyperactivity disorder: a pilot study
dc.typeJournal Article
dc.source.journaltitlePsychiatry research
dc.source.volume211
dc.source.issue1
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/qhs_pp/1105
dc.identifier.contextkey4020108
html.description.abstract<p>We hypothesized that atomoxetine (ATMX) would produce similar brain effects in attention-deficit/hyperactivity disorder (ADHD) as those of methylphenidate (MPH). Eleven ADHD adults performed the Multi-Source Interference Task (MSIT) during functional magnetic resonance imaging (fMRI) at baseline and after 6 weeks of ATMX treatment. ATMX was associated with increased fMRI activation of dorsolateral prefrontal cortex, parietal cortex and cerebellum but not dorsal anterior midcingulate cortex (daMCC). These results suggest that ATMX and MPH have similar but not identical brain effects.</p>
dc.identifier.submissionpathqhs_pp/1105
dc.contributor.departmentDepartment of Quantitative Health Sciences
dc.source.pages88-91


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record